JP Morgan Chase
RLMD icon

JP Morgan Chase’s Relmada Therapeutics RLMD Stock Holding History

JP Morgan Chase’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,103
Closed -$3.06K – 7674
2025
Q2 		$3.06K Buy
5,103
+4,945
+3,130% +$2.54K ﹤0.01% 6476
2025
Q1 		$43 Sell
158
-37,542
-100% -$12.4K ﹤0.01% 7008
2024
Q4 		$19.6K Sell
37,700
-277,359
-88% -$676K ﹤0.01% 6251
2024
Q3 		$1.02M Sell
315,059
-37,557
-11% -$122K ﹤0.01% 4455
2024
Q2 		$1.06M Buy
352,616
+176,638
+100% +$639K ﹤0.01% 4233
2024
Q1 		$818K Buy
175,978
+157,182
+836% +$757K ﹤0.01% 4485
2023
Q4 		$77.8K Buy
18,796
+17,937
+2,088% +$53.1K ﹤0.01% 5844
2023
Q3 		$2.58K Hold
859
– – ﹤0.01% 6502
2023
Q2 		$2.11K Sell
859
-20,122
-96% -$55.6K ﹤0.01% 6328
2023
Q1 		$47K Buy
20,981
+5,478
+35% +$18.9K ﹤0.01% 5724
2022
Q4 		$54K Sell
15,503
-1,589
-9% -$14K ﹤0.01% 5600
2022
Q3 		$633K Buy
17,092
+1,116
+7% +$30.9K ﹤0.01% 4303
2022
Q2 		$304K Buy
15,976
+126
+0.8% +$2.75K ﹤0.01% 4847
2022
Q1 		$427K Buy
15,850
+8,426
+113% +$174K ﹤0.01% 4802
2021
Q4 		$167K Sell
7,424
-3,362
-31% -$74.8K ﹤0.01% 5449
2021
Q3 		$283K Buy
10,786
+344
+3% +$9.21K ﹤0.01% 5048
2021
Q2 		$334K Buy
10,442
+1,251
+14% +$43.5K ﹤0.01% 4951
2021
Q1 		$324K Buy
9,191
+1,121
+14% +$39.2K ﹤0.01% 4928
2020
Q4 		$259K Buy
8,070
+1,088
+16% +$37.4K ﹤0.01% 4711
2020
Q3 		$262K Buy
6,982
+796
+13% +$30.8K ﹤0.01% 4240
2020
Q2 		$277K Buy
+6,186
New +$262K ﹤0.01% 4116

Other funds holding RLMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase's RLMD Position: Q3 2025 in Review

JP Morgan Chase sold out of Relmada Therapeutics (RLMD) in Q3 2025, closing a stake of 5,103 shares — an estimated $3.06K sold.

JP Morgan Chase first reported a position in RLMD in Q2 2020 and held it in 21 quarters. The position peaked at $1.06M in Q2 2024. 44 funds tracked by Wall St. Rank hold RLMD as of Q3 2025.

  • JP Morgan Chase reported no remaining Relmada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 5,103 Relmada Therapeutics shares in Q3 2025, an estimated $3.06K.
  • JP Morgan Chase first reported a position in Relmada Therapeutics in Q2 2020 and held it in 21 quarters.
  • JP Morgan Chase's Relmada Therapeutics position peaked at $1.06M in Q2 2024.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.